1. Home
  2. Insights
  3. Blog
  4. Evolving bioanalytical strategies in the field of biosimilar drug development

Evolving bioanalytical strategies in the field of biosimilar drug development

The shifting biosimilar landscape

Biosimilars play a vital role in expanding patient access to biologic therapies by providing safe, effective and more affordable alternatives to reference products. To achieve approval, sponsors must demonstrate that a biosimilar has no clinically meaningful differences from its reference medicine.

Recent regulatory developments from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are reshaping biosimilar development pathways. These changes place greater emphasis on detecting subtle differences between biosimilars and their reference products through advanced analytical approaches. As a result, sponsors are increasingly expected to generate robust analytical evidence that supports biosimilarity and informs regulatory decision-making.

The role of bioanalysis in biosimilar trials

Bioanalysis is central to the biosimilar development lifecycle. It generates the critical data needed to establish comparability and support regulatory submissions. Key components typically include pharmacokinetic (PK), pharmacodynamic (PD), anti-drug antibody (ADA) and neutralising antibody (NAb) assessments. 

As regulatory expectations evolve, bioanalytical data are becoming increasingly important in demonstrating biosimilarity and reducing development risk.

The impact of regulatory shifts on biosimilar drug development

CMC: Comparative analytical assessment

One of the most significant outcomes of recent regulatory changes is the increased importance of chemistry, manufacturing and controls (CMC) analysis. Regulators are placing greater weight on analytical comparability and process understanding, making it essential to establish a clear connection between manufacturing processes and product attributes.

Sponsors must demonstrate that analytical data reliably support similarity between the biosimilar and the reference product, while also distinguishing between differences that are clinically meaningful and those that are not. Regulatory guidance increasingly supports a risk-based approach, allowing minor differences where there is no impact on safety, efficacy or quality. 

To meet these expectations, developers should expand physicochemical characterisation, strengthen evaluation of impurities and variants, and assess multiple lots of both the biosimilar and reference product across different expiry periods. Head-to-head comparisons remain an important part of building a robust evidence package. 

Bioanalytical assays

Regulators are also increasingly open to reducing or waiving certain comparative clinical efficacy studies when strong analytical and functional evidence is available. This shift elevates the role of PK and PK/PD data in demonstrating biosimilarity. 

As clinical requirements are potentially reduced, confidence in bioanalytical assay performance becomes even more critical. Sponsors should focus on generating high-quality data that accurately assess PK, immunogenicity and relevant PD biomarkers. Assays must be sensitive, reproducible and reflective of the product's mechanism of action. 

A single-assay approach that measures both the biosimilar and originator product without introducing bias can help deliver reliable comparability data. Increased automation can also minimise variability and improve consistency across studies.

Practical implications and recommendations

A strong biosimilar strategy should incorporate the following six elements:

1. Early strategic planning

  • Align analytical, process and regulatory teams early
  • Establish reference product sourcing and comparability plans
  • Define the analytical fingerprint that will guide development
  • Build flexibility into plans to accommodate regulatory feedback

2. Method development and validation roadmap

  • Develop phased plans for both CMC and bioanalytical methods
  • Incorporate orthogonal and high-resolution analytical techniques
  • Ensure PK, PD and immunogenicity methods are appropriately validated for sensitivity and reliability

3. Data strategy and comparability assessment

  • Define similarity criteria based on risk and clinical relevance
  • Use statistical analyses and data trending to support assessments
  • Clearly document and justify any observed differences between products

4. Manufacturing and process integration

  • Link analytical findings directly to process development decisions
  • Use data to strengthen process control and robustness
  • Generate strong comparability evidence between clinical and commercial batches

5. Regulatory interaction and documentation

  • Prepare submissions that clearly explain analytical strategy and comparability findings
  • Connect analytical evidence with clinical pharmacology and PK/PD data
  • Engage early with regulators when pursuing novel or streamlined development approaches

6. Lifecycle management and post-approval analytics

  • Monitor analytical attributes throughout the product lifecycle
  • Maintain readiness for manufacturing and process changes
  • Promote collaboration between analytical, quality, process and regulatory teams to support ongoing comparability

Coordinating bioanalytical and clinical development

Successfully navigating today's biosimilar landscape requires close integration between bioanalytical and clinical development activities. As regulatory expectations continue to evolve, sponsors must ensure analytical evidence, clinical strategy and operational execution remain aligned.

Expertise in biosimilar development can help sponsors evaluate opportunities for reduced clinical programmes, design appropriate PK studies, select suitable patient populations and generate the data required to support regulatory submissions. Strong coordination across analytical, clinical and regulatory disciplines is increasingly important for efficient development and successful approval. 

Conclusion

Biosimilar development is entering a new era in which analytical evidence carries greater regulatory significance than ever before. Sponsors that invest in robust CMC analytics, high-confidence bioanalytical assays and integrated development strategies will be best positioned to meet evolving regulatory expectations and accelerate pathways to approval.

In this section

Connect with us